Psychiatric Presentation of Anti-NMDA Receptor Encephalitis

Dominique Endres 1,2*, Sebastian Rauer 3, Winfried Kern 4, Nils Venhoff 5, Simon J. Maier 1,2, Kimon Runge 1,2, Patrick Süß 6, Bernd Feige 1,2, Kathrin Nickel 1,2, Timo Heidt 7, Katharina Domschke 2,8, Karl Egger 9, Harald Prüss 10,11, Philipp T. Meyer 12 and Ludger Tebartz van Elst 1,2

1 Section for Experimental Neuropsychiatry, Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 2 Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 3 Department of Infectious Diseases, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 4 Division of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 5 Department of Molecular Neurology, University Hospital Erlangen, Erlangen, Germany, 6 University Heart Center Freiburg, Department of Cardiology and Angiology I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 7 Centre for Basics in Neuromodulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 8 Department of Neuroimmunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 9 Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany, 10 German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany, 11 Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Background: Anti-N-methyl D-aspartate (NMDA) receptor encephalitis is an autoimmune condition characterized by neuropsychiatric symptoms, including epileptic seizures, movement disorders, autonomic instability, disturbances of consciousness, paranoia, delusions, and catatonia. Ovarian teratomas and viral infections, typically Herpes simplex viruses, have previously been demonstrated to precipitate anti-NMDA receptor encephalitis, but in many cases, the trigger remains unclear. The detection of anti-NMDA receptor antibodies in cerebrospinal fluid (CSF), in combination with other CSF, electroencephalography (EEG), or magnetic resonance imaging (MRI) abnormalities, typically leads to diagnostic clarification.

Case Presentation: We present the case of a 22-year-old female patient who developed an acute polymorphic psychotic episode 3 days after receiving a booster vaccination against tetanus, diphtheria, pertussis, and polio (Tdap-IPV). Her psychiatric symptoms were initially diagnosed as a primary psychiatric disorder. Her MRI, EEG, and CSF results were non-specific. Anti-NMDA receptor IgG antibodies against the GluN1 subunit were detected in her serum (with a maximum titer of 1:320), but not in her CSF. [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) showed pronounced relative hypermetabolism of her association cortices and a relative hypometabolism of the primary cortices, on the basis of which an anti-NMDA receptor encephalitis diagnosis was made, and treatment with a steroid pulse was initiated. The treatment led to fast and convincing clinical improvement with normalization of neuropsychological findings, considerable improvement of FDG-PET findings, and decreasing antibody titers.
**Conclusion:** The patient’s psychiatric symptoms were most likely caused by anti-NMDA receptor encephalitis. Her polymorphic psychotic symptoms first occurred after she had received a Tdap-IPV booster vaccination. Although the vaccination cannot have caused the initial antibody formation since IgG serum antibodies were detected only 3 days after administration of the vaccine, the vaccine may have exerted immunomodulatory effects. MRI, EEG, and CSF findings were non-specific; however, FDG-PET identified brain involvement consistent with anti-NMDA receptor encephalitis. This case shows the importance of implementing a multimodal diagnostic work-up in similar situations. The negative CSF antibody finding furthermore fits to the hypothesis that the brain may act as an immunoprecipitator for anti-NMDA receptor antibodies.

**Keywords:** anti-NMDA receptor encephalitis, encephalopathy, autoimmune psychosis, antibodies, steroids, vaccination

**BACKGROUND**

Anti-N-methyl D-aspartate (NMDA) receptor encephalitis was first identified as a paraneoplastic disorder associated with ovarian teratoma (1). Since then, large case series with hundreds of cases have allowed researchers to describe its typical clinical course (2). After a prodromal phase with flu-like symptoms, behavioral abnormalities and acute polymorphic symptoms, often accompanied by catatonic symptoms, are typically observed. In addition, movement disorders, such as dyskinesia or rigidity, autonomous instability, or central hypoventilation, typically occur as the disease progresses, as do disturbances of consciousness. Epileptic seizures may also occur at any time (3, 4). Thus, the typical clinical syndrome is neuropsychiatric in nature and thereby points to an organic cause, but there are occasional cases that present like primary idiopathic psychiatric disorders, typically with catatonia (5, 6). Young women are most frequently affected (2).

Patients with anti-NMDA receptor encephalitis usually have IgG antibodies against the GluN1 subunit of NMDA receptors in their cerebrospinal fluid (CSF) (7–10). Electroencephalography (EEG) results are usually abnormal (3), and in some patients a specific EEG phenomenon, the so-called “extreme delta brush,” has been observed (11). It is well-known that ovarian teratomas and viral infections can trigger autoimmune reactions. In paraneoplastic cases associated with ovarian teratomas, the tumor itself contains NMDA receptors, which are typically found in brain tissue, and this seems to trigger the encephalitic autoimmune response (3). In addition, most authors suggest that virus-induced neuroinflammation can trigger antibody formation. While Herpes simplex is most widely blamed in this context, other viruses or bacteria (e.g., varicella zoster, mycoplasma) may also potentially trigger the encephalitic autoimmune response (3). However, often no specific causes for antibody production can be identified.

Vaccinations may also play a role as unspecific triggers (12, 13). A PubMed search for “vaccination and NMDA” (on 24 April 2019) identified 27 published articles addressing this issue, including two case reports. The first case was reported to have developed anti-NMDA receptor encephalitis 5 weeks after a booster vaccination against tetanus, diphtheria, pertussis, and polio (Tdap-IPV) (14). In the second, a patient was reported as having developed a postural tachycardia syndrome with anti-NMDA receptor antibodies after receiving a human papillomavirus vaccination (15). An additional vaccine-related case was also mentioned in a publication by Wang (12), who reported that an individual developed anti-NMDA receptor encephalitis after receiving a vaccination against Japanese encephalitis. A further search for “vaccination and autoimmune encephalitis” resulted in only 12 results and no case reports.

**CASE PRESENTATION**

Here, we present the case of a 22-year-old female German patient who experienced an acute polymorph psychotic episode after receiving a Tdap-IPV booster vaccination (Repevax®). The patient received the vaccination at the beginning of January 2019 and reported an immediate “strange” feeling. She rapidly developed flu-like symptoms (headache, jittering), and 3 days later, she was admitted to a hospital emergency department with psychosis-like symptoms: She was hearing her thoughts and developed paranoia (e.g., she felt that she was being used as a test subject by the clinic staff). Her neurological and general medical examinations were normal, and her CSF samples, magnetic resonance imaging (MRI) scans of her brain, and the EEG showed no relevant abnormalities. Anti-NMDA receptor IgG antibodies against the GluN1 subunit (titer 1:80 3 days after symptom-onset; titer 1:320 after 6 days, both times using cell-based assay) were detected in her serum, but the CSF antibody testing was negative (3 days after symptom-onset, not performed after 6 days; using cell-based assay). After 6 days, the patient was discharged from the hospital and began outpatient psychotherapy with the assumption that her problems were caused by being separated from her parental home. In the meantime, the patient stopped her vocational training and moved house back to her parents. The mother reported that her daughter behaved like a toddler and that she was helpless, unbalanced, and dependent. She was readmitted to the hospital 47 days after vaccination due to her persistent symptomatology with strong...
Fifty-three days after the vaccination, the patient presented herself to our hospital. At this time, she reported that she had pronounced anxiety, an inability to make decisions, strong restlessness, and sensory overload, and that she was emotionally unstable (i.e., she could suddenly burst into tears) and had cognitive deficits (i.e., was not able to keep conversations for a longer period of time in a concentrated manner). She also reported difficulties in falling asleep and sleeping through the night, reduced appetite, and a weight loss of 4–5 kg over 2 months. In addition, she reported experiencing burning sensations on her chest and head and intermittent tachycardia.

**Diagnostic Findings**

A high-resolution 3 Tesla structural MRI of her brain was normal except for a few slight, non-specific bifrontal white matter lesions (Figure 1). An EEG depicted a β-rhythm (likely related to lorazepam intake), with rare intermittent slow wave activity of 6–7/s. Independent Component Analysis (ICA) showed a frontocentral topography compatible with tiredness (Figure 2). Her CSF basic analysis results were inconspicuous (normal white blood cell count/albumin quotient/protein concentration, no CSF specific oligoclonal bands). In her serum, anti-NMDA receptor GluN1-IgG antibodies were still positive (titer 1:160, using cell-based-assays), while IgA and IgM antibodies were negative. CSF antibody testing was again negative, including biochip assays, cell-based assays, and tissue testing. An [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) examination showed a pronounced relative hypermetabolism of parts of the association cortices and a relative hypometabolism of the primary cortices, well compatible with encephalitis (Figure 3). A whole-body FDG-PET/CT detected no lesions suspicious of malignancy, including no ovarian teratoma. A gynecologic ultrasound and an MRI of the abdomen were unremarkable. A long-term electrocardiogram (ECG) showed recurrent sinus tachycardia that stopped at night (Figure 4). Neuropsychological testing showed significant deficits in working memory (Figure 5). All diagnostic findings are summarized in Table 1.
FIGURE 3 | An [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) examination at baseline showed a pronounced relative hypermetabolism of parts of the association cortices and mild relative hypometabolism of the primary cortices, consistent with encephalitis. These metabolic findings markedly improved at follow-up. (Upper panel) Transaxial FDG-PET images at baseline and follow-up. (Middle and lower panel) Metabolic deviations from healthy controls, given as three-dimensional stereotactic surface projections (3D-SSP), color-coded as Z score (middle, relative metabolic increases; lower, relative metabolic decreases). All analyses were performed with Neurostat/3D-SSP [LIT] (16).
Illness, Somatic, and Family Histories

The patient’s history was negative for in-utero or birth complications, febrile convulsions, craniocerebral trauma, or inflammatory brain diseases. During her first two decades of life, she had no evidence of a developmental disorder such as autism spectrum syndrome, attention deficit hyperactivity disorder, or a tic syndrome. The patient described herself as a rather anxious and insecure person; however, she clearly did not fulfill the criteria for any personality, affective, or anxiety disorder. She had no history of cancer or of autoimmune, neurological, or other somatic disorders. Apart from her paternal grandfather having suffered from Alzheimer’s disease she had no family history of psychiatric disorders (including her siblings, parents, and grandparents). Her maternal grandmother had died of a pancreatic carcinoma, her maternal grandfather had died of an unspecified tumor at the age of 38.

Treatment and Outcome

Lorazepam led to a slight improvement in the patient’s anxiety symptoms. After pausing the medication at the patient’s request, anxiety symptoms became more severe. We then treated her with 7.5 mg diazepam. A steroid pulse (5 × 500 mg methylprednisolone, with oral tapering from 40 mg and halving every week over 4 weeks; further reductions took place in 2 mg steps) was performed for immunological treatment. Directly after the steroid pulse, we were able to discontinue diazepam without any worsening of the patient’s anxiety symptoms. On the 5th day of the steroid pulse, the patient reported that she felt well.
again. Over the following 2 weeks, her fears and ambivalence were greatly reduced, her emotions stabilized, and neither inner restlessness nor stimulus overload occurred. A slight form of sleeping disorder persisted; however, her appetite improved. The burning sensations in the chest and head no longer occurred. Follow-up cognitive testing results were within the normal range (Figure 5), and a follow-up FDG-PET (20 days after starting the steroid pulse) showed considerable improvements of the metabolic findings (Figure 3). Her anti-NMDA IgG antibody titers decreased (1:40 ~1 week after steroid pulse and 1:80 ~2 weeks after steroid pulse treatment, using cell-based assays in both analyses). Approximately half a year after the steroid pulse treatment, the patient was completely free of symptoms.

**DISCUSSION**

Our case report describes a female patient with anti-NMDA receptor encephalitis with isolated psychiatric manifestation presenting with acute polymorphic psychotic symptoms that
developed directly after the patient had received a Tdap-IPV booster vaccination, most probably in the context of preexisting anti-NMDA receptor IgG antibodies.

**Diagnostic and Pathophysiological Considerations**

Basic diagnostic procedures using EEG, MRI, and CSF examinations only showed non-specific findings. While the patient initially displayed acute polymorphic psychotic symptoms, she did not present the typical neurological symptoms of encephalitis or encephalopathy, such as movement disorders or epileptic seizures, and her psychiatric symptoms were initially misdiagnosed as a primary mental disorder. However, her vegetative symptom (sinus tachycardia) was typical for anti-NMDA receptor encephalitis, possibly caused by ketamine effects (18). However, since the sinus tachycardia only occurred during the day, it was more likely due to the patient’s anxiety than to a primarily antibody-induced genesis. There were no indications of cancer, particularly ovarian teratoma, neither from the whole-body FDG-PET/CT nor from the gynecological examination. Also, there was no observed viral association nor any preexisting immunological predisposition.

The combination of GluN1-IgG antibodies in the patient’s serum and the FDG-PET finding of relative hypermetabolism in the patient’s association cortex and a relative hypometabolism of the primary cortices led us to the probable diagnosis of anti-NMDA receptor encephalitis (19). Primary vaccination-induced encephalitis seemed less likely due to the clinical course and the FDG-PET findings, the latter of which were consistent with anti-NMDA receptor encephalitis (20–22), including an increased frontal to occipital metabolic ratio that markedly improved upon treatment (23). Indeed, the present patient showed strong frontal hypermetabolism and occipital hypometabolism at baseline, which resolved almost entirely after treatment.

However, due to the timing of symptom onset, there was a possible association with the Tdap-IPV booster vaccination. The presence of isolated anti-NMDA receptor IgG antibodies in the acute phase (IgG antibodies are typically not detectable in the first week after antigen contact) and the rapid onset of symptoms after vaccination clearly indicate the presence of preexisting antibodies or latent, non-clinically manifest encephalitis. Therefore, the vaccination cannot be the initial reason for anti-NMDA receptor antibody production. However, vaccinations physiologically lead to an immunological response with T-cell and B-cell activation. Preexisting specific T- and B-lymphocyte clones might have been re-stimulated, causing them to proliferate and leading to excessive antibody synthesis. Indeed, recent work suggested that antibody-secreting cells releasing functional anti-NMDA-R antibodies are part of the human naïve B cell repertoire and might thus be much more common than previously assumed (24). It is possible that the vaccine’s effect of boosting antibody production led to a short-term increase in the patient’s anti-NMDA receptor antibody levels, which could in turn have caused her clinical symptoms. One could also speculate that a temporary dysfunction of the blood-brain-barrier function might have led to increased antibody levels in the central nervous system (CNS).

In summary, it can be hypothesized that too many anti-NMDA-R antibodies were present in the CNS for a short time and that this has led to a reversible internalization of the anti-NMDA receptors, thereby altering glutamatergic signaling and, consequently, changing neuronal glucose metabolism, with the described FDG-PET alterations and psychiatric symptoms [c.f. (6, 8, 25)]. The FDG-PET finding probably does not reflect classic neuroinflammation, so it may be better to speak of encephalopathy rather than encephalitis in such cases [c.f. (8, 26)].

Normally, antibody detection in CSF characterizes anti-NMDA receptor encephalitis (7–9). The negative CSF result in the patient presented here is nonetheless valid because neither the biochip nor cell-based assays nor the tissue tests were conspicuous. The inconspicuous CSF finding could be due to the relatively low antibody levels compared to typical anti-NMDA receptor encephalitis with broader neurological symptoms (i.e., epileptic seizures). In the present constellation, it is plausible that all antibodies reaching the CNS compartment were bound to brain tissue. Laboratory experiments have shown that the brain can act as an immunoprecipitator for anti-NMDA receptor antibodies (27). Such cases with negative CSF findings could be associated with milder psychiatric manifestations. A similar situation has been found in neumyelitis optica spectrum disorders: Aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies develop in the periphery, but if AQP4 or MOG antibodies reach the CNS, they can have pathological effects. They also typically cannot be detected in the CSF, and even oligoglcan bands are usually negative in those affected (28).

To date, only one comparable report of an association between anti-NMDA receptor antibodies and Tdap-IPV booster vaccination has been published, in which a 15-year-old boy developed anti-NMDA receptor encephalitis 5 weeks after receiving the vaccination. This previous patient presented with a severe neuropsychiatric syndrome with dyskinesia and choreatiform movements, and antibodies were also detected in his CSF; however, detailed information about antibody type was not reported (14).

**Clinical Implications**

A study of the Tdap vaccination without the additional inclusion of IPV found that there were neurological complications in 41 out of 2,090 vaccinated persons, including three who suffered from encephalitis/encephalopathy. The same study also reported demyelinating disorders (N = 4), seizures (N = 7), Bell’s palsy (N = 7), and Guillain-Barré syndrome (N = 10) (29).

Future research should investigate whether patients who report neurological side effects after receiving the Tdap-IPV booster vaccination are positive for anti-NMDA receptor antibodies. Antibody status could then be used to warn patients against vaccination side effects.

In addition, our case shows that an inconspicuous CSF anti-NMDA receptor antibody status does not rule out brain involvement. Despite non-specific MRI, EEG, and CSF findings, profound metabolic changes suggestive of encephalitis may be detected using FDG-PET. This case therefore demonstrates the importance of using multiple modes of examination to clarify and confirm or reject diagnosis in patients who are
This case report shows a possible association between vaccination and PET changes. PET receptor antibodies could only be shown indirectly via FDG-PET since the possible disease-causing effects of anti-NMDA receptor antibodies could only be shown indirectly via FDG-PET changes.

CONCLUSIONS

This case report shows a possible association between vaccination and the immediate development of anti-NMDA receptor encephalitis in a young female patient with likely preexisting anti-NMDA receptor antibodies. Since IgG antibodies were already initially detectable, the vaccination cannot have led to the initial antibody formation, but it may have exerted immunomodulatory effects. The further particularities of our case are the patient's mild psychiatric manifestation that mimicked an idiopathic psychiatric syndrome, her non-specific basic diagnostics (MRI, EEG, and CSF), and ultimate diagnostic clarification by FDG-PET. Detection of an immunological cause was essential, since it suggested immunosuppressive treatment, which led to rapid clinical improvement.

DATA AVAILABILITY STATEMENT

All necessary data can be found in the paper.

REFERENCES

1. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. (2007) 61:25–36. doi: 10.1002/ana.21050
2. Titulaer MJ, McCracken L, Gabilondo I, Armandegi T, Glaser C, Lizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. (2013) 12:157–65. doi: 10.1016/S1474-4422(12)70310-1
3. Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. (2017) 97:839–87. doi: 10.1152/physrev.00010.2016
4. Gurrera RJ. Recognizing psychiatric presentations of anti-NMDA receptor encephalitis in children and adolescents: a synthesis of published reports. Psychiatry Clin Neurosci. (2019) 73:262–8. doi: 10.1111/pcn.12821

ETHICS STATEMENT

Written informed consent was obtained for the publication of any images or data included in this article.

CONSENT FOR PUBLICATION

The patient has given her signed written informed consent for this case report, including the presented images, to be published.

AUTHOR CONTRIBUTIONS

DE performed the data research, and wrote the paper. DE and LT treated the patient. SR performed the neurological interpretation. HP supported the neurological interpretation and performed the tissue antibody tests. BF and LT performed the EEG analyses. WK performed the infectiological interpretation. TH interpreted the cardiological findings. PM was responsible for the nuclear medicine investigations and interpretation. KE and SM performed and interpreted the MRIs. NV performed the rheumatological measurements and interpreted the results. KR, PS, KN, KD, and LT supported the clinical interpretation. All authors were critically involved in the theoretical discussion and composition of the manuscript. All authors read and approved the final version of the manuscript.

FUNDING

The article processing charge was funded by the German Research Foundation (DFG) and the University of Freiburg in the funding program Open Access Publishing.

ACKNOWLEDGMENTS

DE was supported by the Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg. PS was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)-270949263/GRK2162.

5. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol. (2013) 70:1133–9. doi: 10.1001/jamaneurol.2013.3216
6. Endres D, Perlov E, Stich O, Rauer S, Maier S, Waldkircher Z, et al. Hypoglutamatergic state is associated with reduced cerebral glucose metabolism in anti-NMDA receptor encephalitis: a case report. BMC Psychiatry. (2015) 15:186. doi: 10.1186/s12888-015-0552-4
7. Lepoldt F, Armandegi T, Dalmau J. Autoimmune encephalopathies. Ann NY Acad Sci. (2015) 1338:94–114. doi: 10.1111/nyas.12553
8. Endres D, Bechter K, Priess H, Hasan A, Steiner J, Lepoldt F, et al. [Autoantibody-associated schizophreniform psychoses: clinical symptomatology]. Nervenarzt. (2019) 90:547–63. doi: 10.1007/s00115-019-0700-2
9. Teytart van Elst L, Bechter K, Priess H, Hasan A, Steiner J, Lepoldt F, et al. Autoantibody-associated schizophreniform psychoses: pathophysiology, diagnostics, and treatment. Nervenarzt. (2019) 90:745–61. doi: 10.1007/s00115-019-0735-1
10. Tebartz van Elst L, Suß P, Endres D. Autoimmunenzephalitiden in der Psychiatrie. CME-Fortbildung. InFo Neurol Psychiatri. (2019). doi: 10.1007/s15005-019-0022-5

11. Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmu J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. (2012) 79:1094–100. doi: 10.1212/WNL.0b013e3182698cd8

12. Wang H. Anti-NMDA receptor encephalitis and vaccination. Int J Mol Sci. (2017) 18:E193. doi: 10.3390/ijms18010193

13. Wang H. A protocol for investigating the association of vaccination and anti-NMDA receptor encephalitis. Front Biochem. (2018) 10:229–37. doi: 10.2741/s51

14. Hofmann C, Baur MO, Schrot H. Anti-NMDA receptor encephalitis after Tdap-IPV booster vaccination: cause or coincidence? J Neurol. (2011) 258:500–1. doi: 10.1007/s00415-011-5757-3

15. Blüthgen S, Brook J. Postural tachycardia syndrome (POTS) with anti-NMDA receptor antibodies among human papillomavirus vaccination. Immuno Res. (2017) 65:282–4. doi: 10.1007/s12026-016-8855-1

16. Minoshima S, Frey KA, Koepp RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. (1995) 36:1238–48.

17. Nieves-Moreno M, Martinez-de-la-Casa JM, Cifuentes-Canorea P, Sastre-Báñez M, Santos-Bueso E, Sáenz-Francés F, et al. Normative database for separate inner retinal layers thickness using spectral domain optical coherence tomography in Caucasian population. J Ophthalmol. (2017) 12:e0180450. doi: 10.1371/journal.pone.0180450

18. Dalmu J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. (2008) 7:1091–8. doi: 10.1016/S1474-4422(08)70224-2

19. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. (2016) 15:391–404. doi: 10.1016/S1474-4422(15)00401-9

20. Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol. (2013) 266:2744–53. doi: 10.1007/s00415-013-7048-2

21. Heine J, Prüss H, Bartsch T, Ploner CJ, Paul E, Finke C. Imaging of autoimmune encephalitis—Relevance for clinical practice and hippocampal function. Neuroscience. (2015) 309:68–83. doi: 10.1016/j.neuroscience.2015.05.037

22. Bacchi S, Franke K, Wewegama D, Needham E, Patel S, Menon D. Magnetic resonance imaging and positron emission tomography in anti-NMDA receptor encephalitis: a systematic review. J Clin Neurosci. (2018) 52:54–9. doi: 10.1016/j.jocn.2018.03.026

23. Leyboldt F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T, et al. Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry. (2012) 83:681–6. doi: 10.1136/jnnp-2011-301969

24. Wenke NK, Kreye J, Andrzejak E, van Casteren A, Leubner I, Murguieto MS, et al. N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NRI subunit. Ann Neurol. (2019) 85:771–6. doi: 10.1002/ana.25460

25. Ehrenreich H. Autoantibodies against the N-Methyl-D-Aspartate receptor subunit NRI: untangling apparent inconsistencies for clinical practice. Front Immunol. (2017) 8:181. doi: 10.3389/fimmu.2017.00181

26. Blüthgen S, Kästner A, Steiner J, Schneider A, Hettling B, Poggi G, et al. The brain as immunoprecipitator of serum autoantibodies against N-Methyl-D-aspartate receptor subunit NRI. Ann Neurol. (2016) 79:144–51. doi: 10.1002/ana.24545

27. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neurol Neurosurg Psychiatry. (2018) 15:134. doi: 10.1136/jnnp-2018-31144-2

28. Castillo-Gomez E, Sastre-Ibáñez M, Santos-Bueso E, Sáenz-Francés F, et al. Anti-NMDA receptor antibodies after human papillomavirus vaccination. J Neuroinflammation. (2018) 15:134. doi: 10.3389/fninf.2018.00782

29. Chang S, O’Connor PM, Slade BA, Woo EJ. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005–2007. Vaccine. (2013) 31:1447–52. doi: 10.1016/j.vaccine.2012.10.097

Conflict of Interest: SR: receiving consulting and lecture fees, grant, and research support from Bayer Vital, Biogen, Merck Serono, Novartis, Sanofi-Aventis, Genzyme, Roche, and Teva. Furthermore, SR indicates that he is a founding executive board member of Ravo Diagnostika GmbH Freiburg. LT: advisory boards, lectures, or travel grants within the last 3 years: Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen, and Cyberonics.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Endres, Rauer, Kern, Venhoff, Maier, Runge, Süß, Feige, Nickel, Heidt, Domschke, Egger, Prüss, Meyer and Tebartz van Elst. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.